10 Clinical Trials Of 2024 – Hits, Misses And Some In Between

While quieter than some recent years, 2024 did produce several clinical trial readouts destined to have an impact on their respective markets. Here, in roughly chronological order, Scrip takes a look at the 10 clinical stories that got readers clicking the most over the past 12 months.

2024-2025 Scrip Perspectives — (Shutterstock)

2024 got off to a good start for Vertex with positive Phase III studies of its novel pain therapy, suzetrigine (then known as VX-548), reported in January.

The non-opioid, oral selective inhibitor of NaV1.8 – a voltage-gated sodium channel that plays a key role in pain signaling...